The Parkinson and Movement Disorder Institute
Neurology
Dr. Daniel D. Truong, MD
|
|
Give Review
Daniel Truong is an expert in the field of Neurology. He attended Medical University of South Carolina. He received 6 awards: "Top Doctors:LA Area", "Top Doctors:San Diego Area", "Honorary member", "Top Doctors:Southern California", "CMS Meaningful Use Stage 1 Certification" and "Fellow". Daniel Truong is also published. He has 101 publications published. The lastest publication: "Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients.' Daniel D. Truong accepts Medicare payments and is registered with Medicare.gov.
Publications
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's Disease (EASED Study).
- Treatment of myoclonus-dystonia Syndrome with tetrabenazine.
- A rare sequence variant in intron 1 of THAP1 is associated with primary Dystonia.
- Role of G?(olf) in familial and sporadic adult-onset primary Dystonia.
- Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
- Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement Disorders.
- AbobotulinumtoxinA (Dysport) dosing in cervical Dystonia: an exploratory analysis of two large open-label extension studies.
- The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary Dystonia.
- Case studies in the advancement of Parkinson's Disease.
- Natural history of posttraumatic cervical Dystonia.
- Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: therapeutic implications for Parkinson's dise...
- Posthypoxic Myoclonus animal models.
- Antimyoclonic and neuroprotective effects of lamotrigine in an animal model of cardiac arrest.
- Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
- Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global Cerebral hypoxia and reperfusion.
- Development of botulinum toxin therapy.
- Botulinum toxin therapy.
- A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report.
- Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
- [Neuroleptic malignant Syndrome (dopamine-dependent malignant hyperthermia). 4 different cases].
- Rabbit Syndrome treated with botulin.
- Clinical evaluation of bidirectional torticollis.
- Movement Disorders in mitochondrial myopathies. A study of nine cases with two autopsy studies.
- An early description of Dystonia: translation of Schwalbe's thesis and information on his life.
- Posttraumatic torticollis.
- Diphenhydramine is effective in the treatment of idiopathic Dystonia.
- Botulinum toxin in treatment of tardive dyskinetic Syndrome.
- Milacemide increases 5-hydroxytryptamine and dopamine levels in rat Brain--possible mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced myoclonus.
- Treatment of oromandibular Dystonia with botulinum toxin.
- Non-chromaffin tissue plus Nerve growth factor reduces experimental parkinsonism in aged rats.
- Therapeutic trial with glycine in Myoclonus.
- Brachial plexopathy after botulinum toxin injections.
- Expression of Bcl-2 and Bax in the frontoparietal cortex of the rat following cardiac arrest.
- Regulation of tyrosine protein kinase receptor Trk-B and motor function in rats following cardiac arrest.
- Effects of GABA uptake inhibitors on posthypoxic Myoclonus in rats.
- Dissociation of the motor effects of (+)-pentazocine from binding to sigma 1 sites.
- Clinical profile of various sub-types of writer''s cramp.
- Caffeine and progression of Parkinson Disease.
- Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine.
- Hemifacial spasm producing Tremor-like movements of the head.
- Chorea and related disorders.
- Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells.
- Glycine involvement in DDT-induced Myoclonus.
- Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.
- Clinical evidence of genetic anticipation in adult-onset idiopathic Dystonia.
- Parkinson''s Disease Revisited.
- Astrocyte-derived growth factor (S100 beta) and motor function in rats following cardiac arrest.
- The natural history of embouchure Dystonia.
- Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson Disease.
- Chronic treatments with 5-HT1A agonists attenuate posthypoxic Myoclonus in rats.
- Botulinum toxin therapy of laryngeal muscle hyperactivity Syndromes: comparing different botulinum toxin preparations.
- Alterations of Brain levels of phosphoinositidase-C-linked Gq alpha/G11 alpha proteins and motor function in rats after cardiac arrest.
- Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical Dystonia patients.
- Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder.
- Involvement of 5-HT2 receptors in posthypoxic stimulus-sensitive Myoclonus in rats.
- Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism.
- Animal models of Myoclonus.
- Antimyoclonic effect of gabapentin in a posthypoxic animal model of Myoclonus.
- Involvement of GABA(A) receptors in Myoclonus.
- Evidence for the effectiveness of botulinum toxin for sialorrhoea.
- BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical Dystonia patients (preliminary study).
- Botulinum toxin in blepharospasm and oromandibular Dystonia: comparing different botulinum toxin preparations.
- Association between Brain indole levels and severity of posthypoxic myoclonus in rats.
- Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson''s Disease.
- Cervical Dystonia severity scale reliability study.
- Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign Essential blepharospasm: a randomized, placebo-controlled, phase II trial.
- Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic Myoclonus.
- Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations.
- Intracisternal administration of glibenclamide or 5-hydroxydecanoate does not reverse the neuroprotective effect of ketogenic diet against ischemic Brain injury-induce...
- Novel rat cardiac arrest model of posthypoxic Myoclonus.
- Novel THAP1 sequence variants in primary Dystonia.
- Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical Dystonia.
- Ketogenic diet prevents cardiac arrest-induced Cerebral ischemic neurodegeneration.
- Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder.
- Effects of selective serotonergic ligands on posthypoxic audiogenic Myoclonus.
- Evidence for effectiveness of botulinum toxin for hyperhidrosis.
- Efficacy and safety of botulinum type A toxin (Dysport) in cervical Dystonia: results of the first US randomized, double-blind, placebo-controlled study.
- Animal model of posthypoxic Myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization.
- Animal models of posthypoxic Myoclonus: I. Development and validation.
- Animal models of Myoclonus: an overview.
- Motor complications in Parkinson Disease: clinical manifestations and management.
- Ketogenic diet prevents seizure and reduces myoclonic jerks in rats with cardiac arrest-induced Cerebral hypoxia.
- Management of non-motor symptoms in advanced Parkinson Disease.
- Post-hypoxic animal model of Myoclonus.
- "Dystonic" body perception in childhood Dystonia.
- NMDA receptor-mediated excitotoxicity contributes to the Cerebral hypoxic injury of a rat model of posthypoxic myoclonus.
- Molecular defects of the Dystonia-causing torsinA mutation.
- Botulinum toxin: clinical use.
- Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
- Post-hypoxic myoclonus induces Fos expression in the reticular thalamic nucleus and neurons in the Brainstem.
- Expanding use of botulinum toxin.
- Therapeutic strategies for nonmotor symptoms in early Parkinson''s Disease: the case for a higher priority and stronger evidence.
- Prevalence and diagnostic challenge of Dystonia in Thailand: a service-based study in a tertiary university referral centre.
- Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical Dystonia.
- (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y cells.
- Memantine exacerbates myoclonic jerks in a rat model of posthypoxic Myoclonus.
- Myoclonus and parkinsonism.
- Current clinical applications of botulinum toxin.
- Botulinum toxins revisited.
- Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson''s Disease.
Schools
University of Freiburg
Med University Sc
St Barbara Hospital
St Marien Hospital
National Hospital Queens Square
Neurol InstColumbia University
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
- Non-Cosmetic Chemodenervation
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Bell's Palsy
- Brachial Plexus Palsy
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:San Diego Area
- Honorary member
- Top Doctors:Southern California
- CMS Meaningful Use Stage 1 Certification
- Fellow
Education
-
Medical University of South Carolina -
Albert Ludwigs University Faculty of Medicine
Hospital
-
Fountain Valley Regional Hospital and Medical Center
Drug Facts
| NPI NUMBER | 1992720916 | |
| NPPES Provider LastName | TRUONG | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 927085153 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 4431.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992720916 |
| Last Name Of The Provider | TRUONG |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Duc M. Vu, MD |
|
|
Dr. George C. Wang, MD |
|
Dr. Monquen Huang, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Panos Z. Marmarelis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nguyen N. Thong, MD |
|
Dr. William Hornstein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hae-Ryong Oh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tawny Ngo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole H. Cobo, MD
This Doctor is OpenDoctor Recommended.
|